SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is seeing significant volatility as market participants weigh conflicting signals between geopolitical risks in the Strait of Hormuz and a shift toward seasonal demand weakness. While some traders are focused on potential supply disruptions driving short-term spikes, others are prioritizing the transition to the shoulder season and anticipating that increased domestic production will ultimately weigh on prices.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors await a critical Supreme Court decision regarding patent infringement that could reshape 'skinny label' drug regulations. Meanwhile, community sentiment is heavily focused on the company's recent move toward profitability and anticipation that its cash-positive position and intellectual property might attract potential acquisition interest during the J.P. Morgan Healthcare Conference.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as market participants weigh geopolitical instability in the Middle East against shifting inflationary expectations. Traders are actively debating whether the ongoing energy sector tensions and rhetoric surrounding potential infrastructure impacts will lead to a broader market correction or serve as a buying opportunity for dip-buyers.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys is drawing significant attention following a $2 billion strategic investment from Nvidia, which reinforces a multi-year partnership to advance AI-driven chip design and engineering workflows. Investors are actively debating the long-term growth potential of this alliance, weighing concerns over share dilution and macroeconomic sensitivity against the company's critical role in the accelerating AI infrastructure build-out.

Linde Plc is a global industrial gases and engineering company. It designs and builds equipment that produces industrial gases. The company also offers gas production and processing services such as olefin plants, natural gas plants, air separation plants, hydrogen and synthesis gas plants and other types of plants. Its primary products are atmospheric gases and process gases. The company operates through the following reportable segments: Americas, EMEA APAC and Engineering. The Americas segment operates production facilities primarily in the United Sates, Canada, Mexico and Brazil. The EMEA segment has production facilities primarily in Germany, France, Sweden, the Republic of South Africa, and the United Kingdom. The APAC segment has production facilities located primarily in China, Australia, India, South Korea and Thailand. The Engineering segment designs and constructs turnkey process plants for third-party customers as well as for the gases businesses in many locations worldwide. Linde was founded by Carl Paul Gottfried von Lind in 1879 and is headquartered in Woking, the United Kingdom.

Linde Plc.

Linde ($LIN) is trending following multiple analyst upgrades and positive sentiment surrounding its strategic positioning in the clean energy and hydrogen sectors. The market is actively discussing the company's resilience, its role in long-term infrastructure projects, and its recent strong earnings execution.

Air Products & Chemicals, Inc. engages in the manufacture and distribution of atmospheric gases. It operates through the following segments: Americas, Asia, Europe, Middle East and India, and Corporate and Other. The Americas, Asia, Europe, and Middle East and India segments focuses on producing and selling gases to customers, including those in refining, chemicals, metals, electronics, manufacturing, medical, and food industries. The Corporate and Other segment is involved in sales of cryogenic and gas processing equipment for air separation that is sold worldwide to customers in a variety of industries, including chemical and petrochemical manufacturing, oil and gas recovery and processing, and steel and primary metals processing. The company was founded by Leonard Parker Pool on September 30, 1940 and is headquartered in Allentown, PA.

Air Products & Chemicals Inc.

Air Products & Chemicals is currently drawing attention as investors weigh institutional confidence, marked by recent insider buying, against concerns regarding project execution and capital expenditure in the clean hydrogen sector. The community is closely monitoring the company's long-term pivot toward energy transition initiatives, viewing its dividend stability as a key pillar amid broader industrial market fluctuations.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing community attention as investors await the launch of its Super App, which is being touted as a potential catalyst for long-term utility and wider institutional adoption. While some participants are actively accumulating positions and discussing staking opportunities, debate persists regarding the project's price action and the impact of upcoming token unlocks on its market performance.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors weigh significant volatility and heavy volume ahead of an anticipated earnings report, while simultaneously navigating a broader defense-sector sell-off driven by macroeconomic and geopolitical uncertainty. The community remains deeply divided, with bulls highlighting the company's aggressive acquisition strategy, new strategic partnerships, and potential for rapid revenue growth, while bears express skepticism regarding share dilution, consistent sell-offs on price rebounds, and the sustainability of its growth model.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

The $DOG community is currently rallying around its status as the leading Bitcoin-native memecoin, actively highlighting its decentralized structure and fixed supply as key advantages over traditional memecoins. Investors are engaging in coordinated buying efforts and leveraging the asset's presence on major exchanges to drive visibility, while maintaining strong conviction in its long-term potential as a primary play within the Bitcoin ecosystem.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing intense volatility as investors debate the impact of the Clarity Act and broader regulatory shifts, with the community split between those accumulating at lower price points and those expressing frustration over stagnant performance. Market sentiment remains polarized, characterized by speculative chatter about potential institutional adoption and frustration over the asset's underperformance compared to other major cryptocurrencies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$207B Market Shift: The Race for Fast Track Approval in Oncology

$207B Market Shift: The Race for Fast Track Approval in Oncology $207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire VANCOUVER, BC, Feb. 5, 2026 Issued on behalf of...

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a clinical master supply agreement with Swiss healthcare company Roche (RHHBY) for hard-to-treat cancer therapies.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply">agreement</a> aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.Checkpoint inhibitors are a type of immunotherapy used to treat cancer. They work by blocking proteins called checkpoints that cancer cells use to evade the immune system.MAIA CEO Vlad Vitoc said that Ateganosine was found to be “highly synergistic and effective” in combination with Roche’s Atezolizumab in preclinical studies.MAIA’s Ateganosine is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.Ateganosine is presently being developed as a second or later line of treatment for NSCLC for patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.On Stocktwits, retail sentiment around MAIA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed unchanged at ‘low’ levels.<figure class="image"><img style="aspect-ratio:630/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_10_02_21_AM_png_d32286ea58.webp" alt="MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits" width="630" height="66"><figcaption>MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the new agreement.<stembedurl>https://stocktwits.com/MoneyHelix/message/618266998</stembedurl>Another opined that it's “not bad news.”<stembedurl>https://stocktwits.com/share97/message/618262353</stembedurl><a href="https://stocktwits.com/symbol/MAIA">MAIA stock </a>is down by 11% this year and by over 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/air-india-boeing-crash-emergency-power-system-may-have-deployed-mid-flight/chls3JTRR2d">Air India Boeing Crash: Report Says Emergency Power System May Have Deployed Mid-Flight, Raising Engine Failure Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Equity

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.


This account has been verified as an official MAIA representative.

Verified Account

MAIA Biotechnology

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

MAIA
MAIA Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAIA News

MAIAMAIA Biotechnology Inc